Cleared Special

K991079 - ACCUSIGN BZO, BIOSIGN BZO, STATUS BZO (FDA 510(k) Clearance)

Class II Toxicology device cleared through the Special 510(k) pathway - typically does not require clinical trials.

K991079 · Princeton BioMeditech Corp. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1999
Decision
20d
Days
Class 2
Risk

K991079 is an FDA 510(k) clearance for the ACCUSIGN BZO, BIOSIGN BZO, STATUS BZO. Classified as Enzyme Immunoassay, Benzodiazepine (product code JXM), Class II - Special Controls.

Submitted by Princeton BioMeditech Corp. (Monmouth Junction, US). The FDA issued a Cleared decision on April 15, 1999 after a review of 20 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3170 - the FDA toxicology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Princeton BioMeditech Corp. devices

Submission Details

510(k) Number K991079 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 26, 1999
Decision Date April 15, 1999
Days to Decision 20 days
Submission Type Special
Review Panel Toxicology (TX)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
67d faster than avg
Panel avg: 87d · This submission: 20d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code JXM Enzyme Immunoassay, Benzodiazepine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3170
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - JXM Enzyme Immunoassay, Benzodiazepine

All 89
Devices cleared under the same product code (JXM) and FDA review panel - the closest regulatory comparables to K991079.
Alinity c Benzodiazepines Reagent Kit
K243498 · Microgenics Corporation · Dec 2024
ONLINE DAT Benzodiazepines II
K221765 · Roche Diagnostics · Dec 2022
CEDIA Benzodiazepine Assay
K190968 · Microgenics Corporation · Dec 2019
DRI Benzodiazepine Assay
K173963 · Microgenics Corporation · Feb 2018
Healgen Multi-Drug Urine Test Cup
K163704 · Healgen Scientific, LLC · Aug 2017
Healgen Multi-Drug Urine Test Cup, Healgen Multi-Drug Urine Test Dip Card
K153597 · Healgen Scientific, LLC · May 2016